Phase 3 Clinical Trials With Primary Completion Dates in November 2026
This is a list of Phase 3 trials with primary completion dates in November 2026 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| CGON | CG Oncology, Inc. | 2026-11-01 | Phase 3 | NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT |
| DBVT | DBV Technologies S.A. | 2026-11-01 | Phase 3 | NCT07003919 | Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) |
| HRMY | Harmony Biosciences Holdings, Inc. | 2026-11-01 | Phase 3 | NCT05066217 | An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome |
| IMUX | Immunic, Inc. | 2026-11-01 | Phase 3 | NCT05134441 | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis |
| IMUX | Immunic, Inc. | 2026-11-01 | Phase 3 | NCT05201638 | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis |
| LLY | Eli Lilly and Company | 2026-11-01 | Phase 3 | NCT06662383 | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity |
| LLY | Eli Lilly and Company | 2026-11-01 | Phase 3 | NCT06914895 | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight |
| LLY | Eli Lilly and Company | 2026-11-01 | Phase 3 | NCT06962280 | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight |
| NAMS | NewAmsterdam Pharma Company N.V. | 2026-11-01 | Phase 3 | NCT05202509 | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease |
| PHVS | Pharvaris N.V. | 2026-11-01 | Phase 3 | NCT05834777 | Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor |
| SRRK | Scholar Rock Holding Corporation | 2026-11-01 | Phase 3 | NCT05626855 | Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab |
| VRCA | Verrica Pharmaceuticals Inc. | 2026-11-01 | Phase 3 | NCT07246590 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) |